Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays.

Cerebrospinal fluid Lipoproteins RT-QuIC Seed amplification assays α-synuclein

Journal

Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600

Informations de publication

Date de publication:
01 04 2023
Historique:
received: 26 08 2022
accepted: 12 03 2023
medline: 4 4 2023
entrez: 3 4 2023
pubmed: 4 4 2023
Statut: epublish

Résumé

Aggregation of α-synuclein (α-syn) is a prominent feature of Parkinson's disease (PD) and other synucleinopathies. Currently, α-syn seed amplification assays (SAAs) using cerebrospinal fluid (CSF) represent the most promising diagnostic tools for synucleinopathies. However, CSF itself contains several compounds that can modulate the aggregation of α-syn in a patient-dependent manner, potentially undermining unoptimized α-syn SAAs and preventing seed quantification. In this study, we characterized the inhibitory effect of CSF milieu on detection of α-syn aggregates by means of CSF fractionation, mass spectrometry, immunoassays, transmission electron microscopy, solution nuclear magnetic resonance spectroscopy, a highly accurate and standardized diagnostic SAA, and different in vitro aggregation conditions to evaluate spontaneous aggregation of α-syn. We found the high-molecular weight fraction of CSF (> 100,000 Da) to be highly inhibitory on α-syn aggregation and identified lipoproteins to be the main drivers of this effect. Direct interaction between lipoproteins and monomeric α-syn was not detected by solution nuclear magnetic resonance spectroscopy, on the other hand we observed lipoprotein-α-syn complexes by transmission electron microscopy. These observations are compatible with hypothesizing an interaction between lipoproteins and oligomeric/proto-fibrillary α-syn intermediates. We observed significantly slower amplification of α-syn seeds in PD CSF when lipoproteins were added to the reaction mix of diagnostic SAA. Additionally, we observed a decreased inhibition capacity of CSF on α-syn aggregation after immunodepleting ApoA1 and ApoE. Finally, we observed that CSF ApoA1 and ApoE levels significantly correlated with SAA kinetic parameters in n = 31 SAA-negative control CSF samples spiked with preformed α-syn aggregates. Our results describe a novel interaction between lipoproteins and α-syn aggregates that inhibits the formation of α-syn fibrils and could have relevant implications. Indeed, the donor-specific inhibition of CSF on α-syn aggregation explains the lack of quantitative results from analysis of SAA-derived kinetic parameters to date. Furthermore, our data show that lipoproteins are the main inhibitory components of CSF, suggesting that lipoprotein concentration measurements could be incorporated into data analysis models to eliminate the confounding effects of CSF milieu on α-syn quantification efforts.

Sections du résumé

BACKGROUND
Aggregation of α-synuclein (α-syn) is a prominent feature of Parkinson's disease (PD) and other synucleinopathies. Currently, α-syn seed amplification assays (SAAs) using cerebrospinal fluid (CSF) represent the most promising diagnostic tools for synucleinopathies. However, CSF itself contains several compounds that can modulate the aggregation of α-syn in a patient-dependent manner, potentially undermining unoptimized α-syn SAAs and preventing seed quantification.
METHODS
In this study, we characterized the inhibitory effect of CSF milieu on detection of α-syn aggregates by means of CSF fractionation, mass spectrometry, immunoassays, transmission electron microscopy, solution nuclear magnetic resonance spectroscopy, a highly accurate and standardized diagnostic SAA, and different in vitro aggregation conditions to evaluate spontaneous aggregation of α-syn.
RESULTS
We found the high-molecular weight fraction of CSF (> 100,000 Da) to be highly inhibitory on α-syn aggregation and identified lipoproteins to be the main drivers of this effect. Direct interaction between lipoproteins and monomeric α-syn was not detected by solution nuclear magnetic resonance spectroscopy, on the other hand we observed lipoprotein-α-syn complexes by transmission electron microscopy. These observations are compatible with hypothesizing an interaction between lipoproteins and oligomeric/proto-fibrillary α-syn intermediates. We observed significantly slower amplification of α-syn seeds in PD CSF when lipoproteins were added to the reaction mix of diagnostic SAA. Additionally, we observed a decreased inhibition capacity of CSF on α-syn aggregation after immunodepleting ApoA1 and ApoE. Finally, we observed that CSF ApoA1 and ApoE levels significantly correlated with SAA kinetic parameters in n = 31 SAA-negative control CSF samples spiked with preformed α-syn aggregates.
CONCLUSIONS
Our results describe a novel interaction between lipoproteins and α-syn aggregates that inhibits the formation of α-syn fibrils and could have relevant implications. Indeed, the donor-specific inhibition of CSF on α-syn aggregation explains the lack of quantitative results from analysis of SAA-derived kinetic parameters to date. Furthermore, our data show that lipoproteins are the main inhibitory components of CSF, suggesting that lipoprotein concentration measurements could be incorporated into data analysis models to eliminate the confounding effects of CSF milieu on α-syn quantification efforts.

Identifiants

pubmed: 37005644
doi: 10.1186/s13024-023-00613-8
pii: 10.1186/s13024-023-00613-8
pmc: PMC10068178
doi:

Substances chimiques

alpha-Synuclein 0
Lipoproteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20

Subventions

Organisme : Parkinson's Disease Foundation
ID : PF-PRF-934916
Pays : United States
Organisme : Associazione Italiana Ricerca Alzheimer
ID : AGYR2020
Organisme : HORIZON EUROPE Marie Sklodowska-Curie Actions
ID : 860197 - MIRIADE

Informations de copyright

© 2023. The Author(s).

Références

Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Cholesterol. 2012;2012:292598
pubmed: 23119149
J Phys Chem B. 2019 May 23;123(20):4380-4386
pubmed: 31034772
Mov Disord. 2021 Oct;36(10):2444-2446
pubmed: 34236720
Chem Commun (Camb). 2018 Jul 14;54(55):7601-7604
pubmed: 29767190
Front Neurosci. 2021 Mar 31;15:647783
pubmed: 33867925
Nat Protoc. 2023 Apr;18(4):1179-1196
pubmed: 36653527
Acta Neuropathol. 2020 Jul;140(1):49-62
pubmed: 32342188
Sci Adv. 2021 May 14;7(20):
pubmed: 33990334
Sci Rep. 2020 Jun 4;10(1):9106
pubmed: 32499567
Methods Enzymol. 2006;413:326-44
pubmed: 17046404
Protein Expr Purif. 2005 Jul;42(1):173-7
pubmed: 15939304
Lancet Neurol. 2021 Mar;20(3):203-212
pubmed: 33609478
Methods Mol Biol. 2019;1948:35-44
pubmed: 30771168
J Mol Neurosci. 2017 Oct;63(2):165-172
pubmed: 28887769
Acta Neuropathol Commun. 2021 Apr 7;9(1):62
pubmed: 33827706
J Biol Chem. 1987 Oct 15;262(29):14352-60
pubmed: 3115992
Mov Disord. 2019 Apr;34(4):536-544
pubmed: 30840785
Anal Chem. 2018 Oct 16;90(20):11962-11971
pubmed: 30211542
Nat Rev Neurol. 2020 Apr;16(4):185
pubmed: 32107475
Acta Neuropathol Commun. 2021 Nov 6;9(1):179
pubmed: 34742348
Mov Disord. 2015 May;30(6):805-12
pubmed: 25227208
Neurology. 2022 Aug 2;99(5):195-205
pubmed: 35914941
EMBO J. 1994 Apr 15;13(8):2007-12
pubmed: 8168497
Acta Neuropathol. 2022 Apr;143(4):453-469
pubmed: 35141810
Nutrients. 2019 Apr 21;11(4):
pubmed: 31010086
Acta Neuropathol. 2021 Dec;142(6):961-984
pubmed: 34514546
Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818
pubmed: 27752516
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1075-1088
pubmed: 34856754
J Lipid Res. 2001 Jul;42(7):1143-51
pubmed: 11441143
JAMA Neurol. 2017 Feb 01;74(2):163-172
pubmed: 27918765
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15
pubmed: 27174096
Phys Chem Chem Phys. 2017 Jan 18;19(3):1839-1846
pubmed: 28000812
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107
Front Neurol. 2018 Jun 06;9:415
pubmed: 29928254
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235
pubmed: 31270237

Auteurs

Giovanni Bellomo (G)

Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, Perugia, Italy. giovanni.bellomo@unipg.it.

Silvia Paciotti (S)

Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, Perugia, Italy.

Luis Concha-Marambio (L)

R&D Unit, Amprion Inc, 11095 Flintkote Av., San Diego, San Diego, CA, 92121, USA.

Domenico Rizzo (D)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.
Department of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3, 50019, Sesto Fiorentino, Italy.

Anna Lidia Wojdaƚa (AL)

Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, Perugia, Italy.

Davide Chiasserini (D)

Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, PerugiaPerugia, Italy.

Leonardo Gatticchi (L)

Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, PerugiaPerugia, Italy.

Linda Cerofolini (L)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.

Stefano Giuntini (S)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.

Chiara Maria Giulia De Luca (CMG)

Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Yihua Ma (Y)

R&D Unit, Amprion Inc, 11095 Flintkote Av., San Diego, San Diego, CA, 92121, USA.

Carly M Farris (CM)

R&D Unit, Amprion Inc, 11095 Flintkote Av., San Diego, San Diego, CA, 92121, USA.

Giuseppe Pieraccini (G)

Department of Health Sciences, CISM Mass Spectrometry Centre, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.

Sara Bologna (S)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.

Marta Filidei (M)

Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, Perugia, Italy.

Enrico Ravera (E)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.
Department of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3, 50019, Sesto Fiorentino, Italy.
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.

Moreno Lelli (M)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.
Department of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3, 50019, Sesto Fiorentino, Italy.
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.

Fabio Moda (F)

Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Marco Fragai (M)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.
Department of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3, 50019, Sesto Fiorentino, Italy.
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.

Lucilla Parnetti (L)

Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Piazzale Lucio Severi 1/8, 06132, Perugia, Italy.

Claudio Luchinat (C)

Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy. luchinat@cerm.unifi.it.
Department of Chemistry "Ugo Schiff", University of Florence, Via Della Lastruccia 3, 50019, Sesto Fiorentino, Italy. luchinat@cerm.unifi.it.
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy. luchinat@cerm.unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH